Proactive and vigilant management of SADRs among patients treated with SLDs are especially important as the access of MDR-TB cases to anti-retroviral treatment (ART) continues to expand and guidelines now recommending treatment of MDR-TB patients with ART regardless of their CD4 count [12]. This evidence concerns the gene CD4 and tuberculosis.